$6.13
Live
0.0%
Downside
Day's Volatility :5.07%
Upside
5.07%
33.12%
Downside
52 Weeks Volatility :63.72%
Upside
45.75%
Period | Hookipa Pharma Inc. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -29.25% | 6.5% | 0.0% |
6 Months | -9.82% | 7.1% | 0.0% |
1 Year | -17.93% | 9.8% | 0.0% |
3 Years | -91.67% | 14.2% | -20.2% |
Market Capitalization | 59.6M |
Book Value | $10.56 |
Earnings Per Share (EPS) | -4.8 |
Wall Street Target Price | 48.33 |
Profit Margin | -88.73% |
Operating Margin TTM | 33.81% |
Return On Assets TTM | -20.19% |
Return On Equity TTM | -50.55% |
Revenue TTM | 53.6M |
Revenue Per Share TTM | 4.97 |
Quarterly Revenue Growth YOY | 1052.3999999999999% |
Gross Profit TTM | -53.0M |
EBITDA | -46.6M |
Diluted Eps TTM | -4.8 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -3.33 |
EPS Estimate Next Year | -6.34 |
EPS Estimate Current Quarter | -0.1 |
EPS Estimate Next Quarter | -0.05 |
What analysts predicted
Upside of 688.42%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 7.6M | - |
Net Income | -16.2M | ↑ 27.62% |
Net Profit Margin | -212.83% | - |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 11.9M | ↑ 56.53% |
Net Income | -34.1M | ↑ 110.3% |
Net Profit Margin | -285.94% | ↓ 73.11% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 19.6M | ↑ 63.99% |
Net Income | -33.8M | ↓ 1.01% |
Net Profit Margin | -172.59% | ↑ 113.35% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 18.4M | ↓ 5.8% |
Net Income | -75.7M | ↑ 123.86% |
Net Profit Margin | -410.16% | ↓ 237.57% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 14.2M | ↓ 22.76% |
Net Income | -65.1M | ↓ 13.9% |
Net Profit Margin | -457.19% | ↓ 47.03% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 20.1M | ↑ 41.27% |
Net Income | -81.6M | ↑ 25.23% |
Net Profit Margin | -405.29% | ↑ 51.9% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 7.8M | ↑ 251.03% |
Net Income | -12.5M | ↓ 19.44% |
Net Profit Margin | -160.19% | ↑ 537.88% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 3.2M | ↓ 59.43% |
Net Income | -19.9M | ↑ 58.57% |
Net Profit Margin | -626.1% | ↓ 465.91% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 2.7M | ↓ 15.65% |
Net Income | -18.0M | ↓ 9.4% |
Net Profit Margin | -672.49% | ↓ 46.39% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 6.9M | ↑ 156.33% |
Net Income | -19.1M | ↑ 5.83% |
Net Profit Margin | -277.65% | ↑ 394.84% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 7.4M | ↑ 7.86% |
Net Income | -24.8M | ↑ 30.17% |
Net Profit Margin | -335.06% | ↓ 57.41% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 36.6M | ↑ 394.11% |
Net Income | 14.4M | ↓ 157.95% |
Net Profit Margin | 39.3% | ↑ 374.36% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 68.3M | ↓ 7.43% |
Total Liabilities | 23.9M | ↓ 79.51% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 143.7M | ↑ 110.61% |
Total Liabilities | 25.8M | ↑ 8.36% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 187.8M | ↑ 30.66% |
Total Liabilities | 31.7M | ↑ 22.63% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 126.0M | ↓ 32.89% |
Total Liabilities | 36.5M | ↑ 15.02% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 170.5M | ↑ 35.23% |
Total Liabilities | 67.9M | ↑ 86.37% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 161.3M | ↓ 5.35% |
Total Liabilities | 71.5M | ↑ 5.22% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 170.5M | ↑ 12.49% |
Total Liabilities | 67.9M | ↑ 77.95% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 163.1M | ↓ 4.32% |
Total Liabilities | 79.6M | ↑ 17.18% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 191.1M | ↑ 17.18% |
Total Liabilities | 78.8M | ↓ 1.04% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 164.0M | ↓ 14.18% |
Total Liabilities | 69.0M | ↓ 12.47% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 161.3M | ↓ 1.63% |
Total Liabilities | 71.5M | ↑ 3.66% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 145.9M | ↓ 9.59% |
Total Liabilities | 41.3M | ↓ 42.15% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -15.0M | ↑ 25.9% |
Investing Cash Flow | -2.2M | ↑ 65.77% |
Financing Cash Flow | 6.9M | ↓ 88.33% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -41.7M | ↑ 178.24% |
Investing Cash Flow | -2.0M | ↓ 7.02% |
Financing Cash Flow | 109.8M | ↑ 1496.84% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -39.3M | ↓ 5.73% |
Investing Cash Flow | -2.4M | ↑ 18.61% |
Financing Cash Flow | 73.4M | ↓ 33.1% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -66.0M | ↑ 67.81% |
Investing Cash Flow | -12.6M | ↑ 430.62% |
Financing Cash Flow | -235.0K | ↓ 100.32% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -20.0M | ↓ 69.71% |
Investing Cash Flow | -5.0M | ↓ 60.12% |
Financing Cash Flow | 72.3M | ↓ 30853.62% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 13.1M | ↓ 179.58% |
Investing Cash Flow | -599.0K | ↓ 37.47% |
Financing Cash Flow | -196.0K | ↓ 254.33% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -2.8M | ↓ 121.68% |
Investing Cash Flow | -274.0K | ↓ 54.26% |
Financing Cash Flow | -735.0K | ↑ 275.0% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -19.3M | ↑ 578.83% |
Investing Cash Flow | -445.0K | ↑ 62.41% |
Financing Cash Flow | 45.8M | ↓ 6333.33% |
Sell
Neutral
Buy
Hookipa Pharma Inc. is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Hookipa Pharma Inc. | -1.25% | -9.82% | -17.93% | -91.67% | -90.44% |
![]() Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
![]() Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
![]() Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
![]() Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Hookipa Pharma Inc. | NA | NA | NA | -3.33 | -0.51 | -0.2 | NA | 10.56 |
![]() Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
![]() Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
![]() Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
![]() Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Hookipa Pharma Inc. | Buy | $59.6M | -90.44% | NA | -88.73% |
![]() Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
![]() Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Insights on Hookipa Pharma Inc.
Revenue is up for the last 4 quarters, 2.67M → 36.59M (in $), with an average increase of 49.4% per quarter
Netprofit is up for the last 2 quarters, -24.81M → 14.38M (in $), with an average increase of 272.6% per quarter
In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 79.5%
In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 278.2%
Baker Bros Advisors LP
Artal Group S A
Knoll Capital Management LP
EcoR1 Capital, LLC
FMR Inc
Vanguard Group Inc
hookipa pharma inc. is a clinical stage company developing products to prevent and cure infectious diseases and cancer. with this goal in mind we created unique and cutting-edge technologies which reprogram and stimulate the immune system. our arenavirus technologies, vaxwave®, a replication-deficient viral vector, and therat®, an attenuated replicating vector, induce potent pathogen-neutralizing antibodies and cd8+ t cells. both, vaxwave® and therat®, can be administered repeatedly while maintaining their efficacy. therat® induced cd8+ t cell responses to tumor antigens reach frequencies and potencies matching or exceeding those observed after adoptive t cell therapy. hookipa’s “off-the shelf” viral vectors are administered systemically. they target dendritic cells in vivo and activate the immune system. in immune-oncology, this mechanism enables to fight solid tumors systemically, both primary and secondary (metastatic). at hookipa we have successfully completed a phase 1 trial of a
Organization | Hookipa Pharma Inc. |
Employees | 151 |
CEO | Mr. Joern Aldag |
Industry | Pharmaceuticals: Major |
A Spac I Acquisition Corp
$6.13
-3.01%
Keyarch Acquisition Corp
$6.13
-3.01%
Connexa Sports Technologies Inc
$6.13
-3.01%
Us Value Etf
$6.13
-3.01%
First Wave Biopharma Inc
$6.13
-3.01%
Global X Msci Next Emerging
$6.13
-3.01%
Fat Projects Acquisition Corp
$6.13
-3.01%
Capital Link Global Fintech
$6.13
-3.01%
Applied Uv Inc
$6.13
-3.01%